Table 1.
Mean CEOAE amplitudes 1–4 kHz (in dB SPL) as a function of sex, condition, and ear
| Total samplea | Left-ear CEOAEb | Right-ear CEOAE | ||||
|---|---|---|---|---|---|---|
| Age: M (SD), range | N | dB SPL: M (SD) | N | dB SPL: M (SD) | N | |
| Trans girlsc | 15.9 (2.4), 11.0–20.0 | 43 | 10.7 (4.1) | 37 | 12.1 (3.8) | 40 |
| Treatment-naïve | 12.6 (0.9), 11.0–14.0 | 10 | 6 | 10 | ||
| GnRHa | 15.2 (1.0), 13.3–17.1 | 14 | 14 | 13 | ||
| GnRHa + CSH | 18.1 (0.8), 16.8–20.0 | 19 | 17 | 17 | ||
| Trans boysd | 15.6 (2.3), 10.3–20.3 | 62 | 12.3 (4.7) | 59 | 12.5 (5.2) | 60 |
| Treatment-naïve | 13.7 (2.4), 10.3–17.3 | 15 | 14 | 13 | ||
| GnRHae | 15.0 (1.6), 12.3–18.0 | 26 | 25 | 26 | ||
| GnRHa + CSHf | 17.8 (1.1), 16.3–20.3 | 21 | 20 | 21 | ||
| Control boys | 14.5 (2.4), 10.8–18.3 | 44 | 12.4 (3.5) | 37 | 12.2 (3.6) | 40 |
| Early adolescent | 12.8 (1.9), 10.8–16.2 | 13 | 10 | 12 | ||
| Mid-adolescent | 13.9 (1.9), 10.8–15.8 | 18 | 15 | 16 | ||
| Late adolescent | 17.1 (0.8), 15.8–18.3 | 13 | 12 | 12 | ||
| Control girls | 14.8 (2.9), 10.8–18.5 | 37 | 14.1 (3.7) | 35 | 15.5 (3.8) | 35 |
| Early adolescent | 12.2 (1.7), 10.8–16.3 | 15 | 14 | 15 | ||
| Mid-adolescent | 15.1 (1.8), 11.5–16.4 | 10 | 9 | 10 | ||
| Late adolescent | 17.9 (0.4), 17.3–18.5 | 12 | 12 | 10 | ||
All control and treatment-naïve participants (except for three treatment-naïve trans girls) participated in our previous study (Burke et al., 2014)
aTotal sample: All participants included in left-ear and/or right-ear analyses
bCEOAE = click-evoked otoacoustic emission
cTrans girls = individuals assigned male at birth
dTrans boys = individuals assigned female at birth
eGnRHa = gonadotropin-releasing hormone analog, puberty suppression
fCSH = cross-sex hormone treatment, estradiol for trans girls, testosterone for trans boys